[mTOR complex activity and metabolic changes as potential targets in solid tumors]

Area of Science:

• Oncology
• Molecular Biology
• Metabolic Pathways

Background:

• Breast tumors exhibit significant metabolic heterogeneity and plasticity.
• The mechanistic target of rapamycin (mTOR) pathway plays a crucial role in cancer metabolism.
• Understanding metabolic adaptations is key to developing effective breast cancer therapies.

Purpose of the Study:

• To investigate the activity and inhibition of mTOR and other metabolic pathways in human breast tumors.
• To assess the clinical significance of these pathways in relation to breast tumor prognosis.
• To explore the potential of targeting metabolic pathways for breast cancer treatment.

Main Methods:

• Utilized ten breast cancer cell lines for in vitro studies.
• Analyzed nearly one hundred human breast tumor biopsy samples.
• Employed immunohistochemical evaluation (IHC panel) to assess protein expression and pathway activity.

Main Results:

• Metabolic and mTOR inhibitor treatments demonstrated moderate, subtype-independent tumor growth inhibition in cell lines, suggesting adaptive mechanisms.
• A subtype-independent correlation was observed between high mTOR activity, increased expression of alternative metabolic pathway proteins, and poor breast tumor prognosis.
• Breast tumors display significant metabolic plasticity, which can be exploited therapeutically.

Conclusions:

• Metabolic targeting and mTOR inhibition show potential but require strategies to overcome tumor adaptation.
• High mTOR activity and associated metabolic pathway alterations are indicators of poor prognosis in breast cancer.
• Immunohistochemical evaluation can identify tumors with high metabolic plasticity and poor prognosis, guiding treatment decisions and patient follow-up.